Potentially effective drugs for the treatment of COVID-19 or MIS-C in children: a systematic review
| Autor: | Zhengxiu Luo, Yaolong Chen, Zhili Wang, Qinyuan Li, Joy James Mafiana, Xiangyang Dang, Weiguo Li, Siya Zhao, Enmei Liu, Yuyi Tang, Lidan Gan, Rafael Gonzalez Cortes, Shuai Peng, Qianling Shi, Qi Zhou, Zijun Wang |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Adolescent medicine.medical_treatment law.invention Randomized controlled trial law Internal medicine medicine Extracorporeal membrane oxygenation Humans Adverse effect Child Glucocorticoids Mechanical ventilation business.industry COVID-19 Immunoglobulins Intravenous Odds ratio Respiration Artificial Systemic Inflammatory Response Syndrome COVID-19 Drug Treatment Methylprednisolone Pediatrics Perinatology and Child Health business medicine.drug Case series Cohort study |
| Zdroj: | European journal of pediatrics. 181(5) |
| ISSN: | 1432-1076 |
| Popis: | The purpose of this systematic review is to evaluate the efficacy and safety of using potential drugs: remdesivir and glucocorticoid in treating children and adolescents with COVID-19 and intravenous immunoglobulin (IVIG) in treating MIS-C. We searched seven databases, three preprint platform, ClinicalTrials.gov, and Google from December 1, 2019, to August 5, 2021, to collect evidence of remdesivir, glucocorticoid, and IVIG which were used in children and adolescents with COVID-19 or MIS-C. A total of nine cohort studies and one case series study were included in this systematic review. In terms of remdesivir, the meta-analysis of single-arm cohort studies have shown that after the treatment, 54.7% (95%CI, 10.3 to 99.1%) experienced adverse events, 5.6% (95%CI, 1.2 to 10.1%) died, and 27.0% (95%CI, 0 to 73.0%) needed extracorporeal membrane oxygenation or invasive mechanical ventilation. As for glucocorticoids, the results of the meta-analysis showed that the fixed-effect summary odds ratio for the association with mortality was 2.79 (95%CI, 0.13 to 60.87), and the mechanical ventilation rate was 3.12 (95%CI, 0.80 to 12.08) for glucocorticoids compared with the control group. In terms of IVIG, most of the included cohort studies showed that for MIS-C patients with more severe clinical symptoms, IVIG combined with methylprednisolone could achieve better clinical efficacy than IVIG alone.Conclusions: Overall, the current evidence in the included studies is insignificant and of low quality. It is recommended to conduct high-quality randomized controlled trials of remdesivir, glucocorticoids, and IVIG in children and adolescents with COVID-19 or MIS-C to provide substantial evidence for the development of guidelines. What is Known:• The efficacy and safety of using potential drugs such as remdesivir, glucocorticoid, and intravenous immunoglobulin (IVIG) in treating children and adolescents with COVID-19/MIS-C are unclear. What is New:• Overall, the current evidence cannot adequately demonstrate the effectiveness and safety of using remdesivir, glucocorticoids, and IVIG in treating children and adolescents with COVID-19 or MIS-C.• We are calling for the publication of high-quality clinical trials and provide substantial evidence for the development of guidelines. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink